Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer’s disease
- Author(s): Behan, DP
- Heinrichs, SC
- Troncoso, JC
- Liu, XJ
- Kawas, CH
- Ling, N
- Souza, EBD
- et al.
Published Web Locationhttps://doi.org/10.1038/378284a0
IN Alzheimer's disease (AD) there are dramatic reductions in the content of corticotropin releasing factor (CRF)1–4, reciprocal increases in CRF receptors1,2, and morphological abnormalities in CRF neurons5 in affected brain areas. Cognitive impairment in AD patients is associated with a lower cerebrospinal fluid concentration of CRF6, which is known to induce increases in learning and memory in rodents7–9. This suggests that CRF deficits contribute to cognitive impairment. The identification in post-mortem brain of CRF-binding protein (CRF-BP)10,11, a high-affinity binding protein that inactivates CRF, and the differential distribution of CRF-BP12 and CRF receptors13, provides the potential for improving learning and memory without stress effects of CRF receptor agonists14. Here we show that ligands that dissociate CRF from CRF-BP increase brain levels of 'free CRF' in AD to control levels and show cognition-enhancing properties in models of learning and memory in animals without the characteristic stress effects of CRF receptor agonists. © 1995, Nature Publishing Group. All rights reserved.
Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.